Processa Pharmaceuticals, Inc. Deferred Federal, State and Local, Tax Expense (Benefit)
Processa Pharmaceuticals, Inc. (PCSA) reported Deferred Federal, State and Local, Tax Expense (Benefit) of -$7.45 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-30.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit · last filed 2023-03-30
- Processa Pharmaceuticals, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2022 was -$7.45M.
- Processa Pharmaceuticals, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2021 was -$3.48M.
- Processa Pharmaceuticals, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2020 was -$3.98M.
- Processa Pharmaceuticals, Inc. deferred federal, state and local, tax expense (benefit) for fiscal 2019 was -$1.27M.
| Period end | Deferred Federal, State and Local, Tax Expense (Benefit) 12 month |
|---|---|
| 2022-12-31 | -$7.45M 10-K · filed 2023-03-30 |
| 2021-12-31 | -$3.48M 10-K · filed 2023-03-30 |
| 2020-12-31 | -$3.98M 10-K · filed 2022-03-30 |
| 2019-12-31 | -$1.27M 10-K · filed 2021-03-25 |
| 2018-12-31 | -$1.23M 10-K · filed 2020-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |